Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ.

Autor: Kay-Marie Lamar, Sasha Bogdanovich, Brandon B Gardner, Quan Q Gao, Tamari Miller, Judy U Earley, Michele Hadhazy, Andy H Vo, Lisa Wren, Jeffery D Molkentin, Elizabeth M McNally

Publikováno v: PLoS Genetics, Vol 12, Iss 5, p e1006019 (2016)

Latent TGFβ binding proteins (LTBPs) regulate the extracellular availability of latent TGFβ. LTBP4 was identified as a genetic modifier of muscular dystrophy in mice and humans. An in-frame insertion polymorphism in the murine Ltbp4 gene associates

Externí odkaz: https://doaj.org/article/35f5807a2cb5426eb37207ef1729b089

Author Correction: High-throughput identification of post-transcriptional utrophin up-regulators for Duchenne muscle dystrophy (DMD) therapy

Autor: Emanuele Loro, Kasturi Sengupta, Donna M. Huryn, Tejvir S. Khurana, Sasha Bogdanovich, David C. Schultz, Kanupriya Whig

Publikováno v: Scientific Reports, Vol 10, Iss 1, Pp 1-1 (2020)
Scientific Reports

Upregulation of endogenous utrophin offers great promise for treating DMD, as it can functionally compensate for the lack of dystrophin caused by DMD gene mutations, without the immunogenic concerns associated with delivering dystrophin. However, pos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d230941d49d0661e0c583c994b95e206
http://link.springer.com/article/10.1038/s41598-020-60885-8

Excess SMAD signaling contributes to heart and muscle dysfunction in muscular dystrophy

Autor: Anastasia Beiriger, Elizabeth M. McNally, Sasha Bogdanovich, Jeffery D. Molkentin, Judy U. Earley, Lisa M. Wren, Quan Q. Gao, Jeffery A. Goldstein, Brandon Gardner, Ann E. Rossi

Publikováno v: Human Molecular Genetics. 23:6722-6731

Disruption of the dystrophin complex causes muscle injury, dysfunction, cell death and fibrosis. Excess transforming growth factor (TGF) β signaling has been described in human muscular dystrophy and animal models, where it is thought to relate to t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa5c296b3dd6f2b74d0409d245cb958a
https://doi.org/10.1093/hmg/ddu390

Intravenous immune globulin suppresses angiogenesis in mice and humans

Autor: Ivana Apicella, Sasha Bogdanovich, Bradley D. Gelfand, Arturo Brunetti, J. Sjef Verbeek, Charles B. Wright, Shengjian Li, Younghee Kim, Laura Tudisco, Tetsuhiro Yasuma, Jeanette H. W. Leusen, Yoshio Hirano, Ana Bastos-Carvalho, Jayakrishna Ambati, Takeshi Mizutani, Sandro De Falco, Valeria Cicatiello, Ingrid E. Lundberg, Benjamin J. Fowler, Balamurali K. Ambati, Adelaide Greco, Valeria Tarallo, Nagaraj Kerur, Sevim Barbasso Helmers, Ondrej Viklicky, Reo Yasuma

Publikováno v: Signal Transduction and Targeted Therapy ( 1 (2016). doi:10.1038/sigtrans.2015.2
info:cnr-pdr/source/autori:Yasuma R, Cicatiello V, Mizutani T, Tudisco L, Kim Y, Tarallo V, Bogdanovich S, Hirano Y, Kerur N, Li S, Yasuma T, Fowler BJ, Wright CB, Apicella I, Greco A, Brunetti A, Ambati BK, Helmers SB, Lundberg IE, Viklicky O, Leusen JH, Verbeek JS, Gelfand BD, Bastos-Carvalho A, De Falco S, Ambati J./titolo:Intravenous immune globulin suppresses angiogenesis in mice and humans./doi:10.1038%2Fsigtrans.2015.2/rivista:Signal Transduction and Targeted Therapy (/anno:2016/pagina_da:/pagina_a:/intervallo_pagine:/volume:1
Signal Transduction and Targeted Therapy
Signal transduction and targeted therapy, 1. Springer Nature

Human intravenous immune globulin (IVIg), a purified IgG fraction composed of ~60% IgG1 and obtained from the pooled plasma of thousands of donors, is clinically used for a wide range of diseases. The biological actions of IVIg are incompletely under

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4093348e195c601186890e5a60286468
https://dspace.library.uu.nl/handle/1874/341293

Human IgG1 antibodies suppress angiogenesis in a target-independent manner

Autor: Tetsuhiro Yasuma, Hiroko Terasaki, Mike Clark, Valeria Cicatiello, Laura Tudisco, Yuichiro Ogura, Wallace Y. Langdon, Judit Z. Baffi, Miho Nozaki, Pierre Bruhns, Younghee Kim, Parthasarathy Arpitha, Sasha Bogdanovich, Nagaraj Kerur, Takeshi Mizutani, Yoshio Hirano, Bradley D. Gelfand, Benjamin J. Fowler, Balamurali K. Ambati, Ivana Apicella, Kathryn L. Armour, Shengjian Li, Sandro De Falco, Ryo Ijima, Hiroki Kaneko, Ana Bastos-Carvalho, Valeria Tarallo, Jeanette H. W. Leusen, Charles B. Wright, Jayakrishna Ambati, J. Sjef Verbeek, Arturo Brunetti, Reo Yasuma, Annamaria Sandomenico, Adelaide Greco, Menotti Ruvo

Publikováno v: Signal Transduction and Targeted Therapy, 1. NATURE PUBLISHING GROUP
Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy, Nature.com, 2016, 1, pp.15001. ⟨10.1038/sigtrans.2015.1⟩
Signal Transduction and Targeted Therapy, 2016, 1, pp.15001. ⟨10.1038/sigtrans.2015.1⟩
Signal Transduction and Targeted Therapy ( 1 (2016): 15001. doi:10.1038/sigtrans.2015.1
info:cnr-pdr/source/autori:Bogdanovich, Sasha; Kim, Younghee; Mizutani, Takeshi; Yasuma, Reo; Tudisco, Laura; Cicatiello, Valeria; Bastos-Carvalho, Ana; Kerur, Nagaraj; Hirano, Yoshio; Baffi, Judit Z; Tarallo, Valeria; Li, Shengjian; Yasuma, Tetsuhiro; Arpitha, Parthasarathy; Fowler, Benjamin J; Wright, Charles B; Apicella, Ivana; Greco, Adelaide; Brunetti, Arturo; Ruvo, Menotti; Sandomenico, Annamaria; Nozaki, Miho; Ijima, Ryo; Kaneko, Hiroki; Ogura, Yuichiro; Terasaki, Hiroko; Ambati, Balamurali K; Leusen, Jeanette Hw; Langdon, Wallace Y; Clark, Michael R; Armour, Kathryn L; Bruhns, Pierre; Verbeek, J Sjef; Gelfand, Bradley D; De Falco, Sandro; Ambati, Jayakrishna/titolo:Human IgG1 antibodies suppress angiogenesis in a target-independent manner./doi:10.1038%2Fsigtrans.2015.1/rivista:Signal Transduction and Targeted Therapy (/anno:2016/pagina_da:15001/pagina_a:/intervallo_pagine:15001/volume:1
Signal transduction and targeted therapy, 1. Springer Nature

Aberrant angiogenesis is implicated in diseases affecting nearly 10% of the world’s population. The most widely used anti-angiogenic drug is bevacizumab, a humanized IgG1 monoclonal antibody that targets human VEGFA. Although bevacizumab does not r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a748982605123f93b3715b7cbf03313
http://hdl.handle.net/11588/636288